Harvard Bioscience, Inc. (HBIO)

Nasdaq: HBIO · Laboratory Analytical Instruments · Holliston, MA · filing with the SEC since 2000

Full chart Alerts Compare

Grade2.8

◀ Past 1.6● Present 3.1▶ Future 3.7

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$86.5M-8.1%

Net income-$56.7M-357.1%

Earnings per share$-1.28-357.1%

Operating cash flow$6.7M+367.3%

Cash$8.6M+109.7%

Debt$35.9M

Shareholders’ equity$13.7M-78.3%

Shares, diluted44.4M+2.0%

Return on equity-412.8%

The recordfrom its filings

Filings in 202645

Newest filingNov 10 · 10-Q

Annual reportMar 13, 2026

Quarterly reportNov 10, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$0.00

Insider buys, 12 months$200,000

Patents granted21

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Sep 2026Revenue $89.4MNet income -$11.8MCash from operations -$681,000the four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 10, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Nov 10, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Sep 22, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Aug 11, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Aug 11, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Aug 11, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Jun 12, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Jun 11, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Jun 11, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Harvard Bioscience, Inc. is classed by the SEC under Laboratory Analytical Instruments (industry code 3826), based in Holliston, MA. Instruments Equipment Software and Accessories was 90% of fiscal 2025 revenue.

Newest on the record

Quarterly report on Nov 10. Before it, current report on Nov 10.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About HBIO

Harvard Bioscience, Inc. is classed by the SEC under Laboratory Analytical Instruments (industry code 3826), based in Holliston, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $87 million and a loss of $57 million (its filed statements).

IndustryLaboratory Analytical Instruments

HeadquartersHolliston, MA

Business modelProduct business

ExchangeNasdaq

Filing since2000

Fiscal year endsDec 31

SEC number (CIK)1123494

Peers on fileRPID, BNGO, NAUT, PRE

Who runs it

Financial performance

In fiscal 2025 Harvard Bioscience’s revenue was $86.55 million, down 8.1% from $94.14 million the year before. It made a net loss of $56.70 million.

Annual report, filed Mar 13, 2026.

Financial statements

The grade

Harvard Bioscience grades 2.8 of 10 against its own industry, the 23 companies in Laboratory Analytical Instruments. All nine metrics are read as filed.

◀ Past1.6

● Present3.1

▶ Future3.7

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton HBIO · research, not advice